Silexion Therapeutics Announces 1-for-15 Reverse Share Split

Grand Cayman, Cayman Islands, July 16, 2025 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (NASDAQ: SLXN) (“Silexion” or the “Company”), a clinical-stage biotechnology company pioneering RNA interference (RNAi) therapies for KRAS-driven cancers, today announced a 1-for-15 reverse share split of its ordinary shares. The reverse share split will become effective after market close on July 28, 2025, and the Company’s ordinary shares will begin trading on a split-adjusted basis on the Nasdaq Capital Market at market open on July 29, 2025, under the existing ticker symbol “SLXN.” A new CUSIP number will be assigned to the post-reverse split shares.

Read more at globenewswire.com